Article Navigation
Article Contents
-
Abstract
Journal Article Accepted manuscript Editor's Choice
, Thomas P Lodise, Pharm.D., Ph.D Corresponding Author: Thomas Lodise, Pharm.D., Ph.D., Professor, Pharmacy Practice, Albany College of Pharmacy and Health Sciences, 106 New Scotland Avenue, Albany, New York, 12208-3492, USA Phone: 518-694-7292; Email: thomas.lodise@acphs.edu Search for other works by this author on: Oxford Academic Sujata M Bhavnani, Pharm.D., M.S., FIDSA Institute for Clinical Pharmacodynamics, Inc. , Schenectady , New York Search for other works by this author on: Oxford Academic Paul G Ambrose, Pharm.D., FIDSA Institute for Clinical Pharmacodynamics, Inc. , Schenectady , New York Search for other works by this author on: Oxford Academic Helio S Sader, M.D., Ph.D., FIDSA JMI Laboratories , North Liberty, Iowa Search for other works by this author on: Oxford Academic David R Andes, M.D Department of Medicine, Department of Medical Microbiology and Immunology, School of Medicine and Public Health and School of Pharmacy, University of Wisconsin-Madison , Madison, Wisconsin Search for other works by this author on: Oxford Academic Jason M Pogue, Pharm.D Department of Clinical Pharmacy, College of Pharmacy, University of Michigan , Ann Arbor, Michigan , USA Alternative Corresponding Author: Jason M. Pogue, Pharm.D., Professor, University of Michigan College of Pharmacy Phone: 734-647-5425; Email: jmpogue@med.umich.edu Search for other works by this author on: Oxford Academic
Clinical Infectious Diseases, ciae328, https://doi.org/10.1093/cid/ciae328
Published:
21 June 2024
Article history
Received:
21 February 2024
Revision received:
13 May 2024
Accepted:
13 June 2024
Published:
21 June 2024
- Split View
- Views
- Article contents
- Figures & tables
- Video
- Audio
- Supplementary Data
-
Cite
Cite
Thomas P Lodise, Sujata M Bhavnani, Paul G Ambrose, Helio S Sader, David R Andes, Jason M Pogue, on behalf of the United States Committee on Antimicrobial Susceptibility Testing (USCAST), Piperacillin/tazobactam Susceptibility Test Interpretive Criteria for Enterobacterales: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing, Clinical Infectious Diseases, 2024;, ciae328, https://doi.org/10.1093/cid/ciae328
Close
Search
Close
Search
Advanced Search
Search Menu
Abstract
The in vitro susceptibility testing interpretive criteria (STIC) for TZP against Enterobacterales were recently updated by the Food and Drug Administration (FDA), Clinical & Laboratory Standards Institute (CLSI), and European Committee on Antimicrobial Susceptibility Testing (EUCAST). The United States Committee on Antimicrobial Susceptibility Testing (USCAST) also recently reviewed TZP STIC for Enterobacterales and arrived at different STIC for Enterobacterales and herein we explain our recommendations and rationale behind them. Based on our review of the available data, USCAST does not recommend TZP STIC for certain Enterobacterales species that have a moderate to high likelihood of clinically significant AmpC production (E. cloacae, C. freundii, and K. aerogenes only) or for third-generation cephalosporin-non-susceptible (3GC-NS) Enterobacterales. USCAST recommends a TZP susceptibility breakpoint of ≤ 16/4 mg/L for third-generation cephalosporin-susceptible (3GC-S) Enterobacterales but only endorses the use of extended infusion TZP regimens for patients with infections due to these pathogens.
susceptibility, piperacillin/tazobactam, Enterobacterales, ESBL, AmpC
Accepted manuscripts
Accepted manuscripts are PDF versions of the author’s final manuscript, as accepted for publication by the journal but prior to copyediting or typesetting. They can be cited using the author(s), article title, journal title, year of online publication, and DOI. They will be replaced by the final typeset articles, which may therefore contain changes. The DOI will remain the same throughout.
This content is only available as a PDF.
© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.
This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/pages/standard-publication-reuse-rights)
Download all slides
Comments
0 Comments
Comments (0)
Submit a comment
You have entered an invalid code
Thank you for submitting a comment on this article. Your comment will be reviewed and published at the journal's discretion. Please check for further notifications by email.
Advertisem*nt
Citations
Views
Altmetric
More metrics information
Metrics
Total Views 0
0 Pageviews
0 PDF Downloads
Since 6/21/2024
Citations
Powered by Dimensions
Altmetrics
See also
-
Commentary
- Susceptibility Test Interpretive Criteria and the Benefit of Diverse Viewpoints
Citing articles via
Google Scholar
-
Latest
-
Most Read
-
Most Cited
More from Oxford Academic
Clinical Medicine
Infectious Diseases
Medicine and Health
Books
Journals
Lincoln, Nebraska
Pittsburg, Pennsylvania
Burlington, Vermont
Long Island, New York
Advertisem*nt